We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Zealand Pharma AS | TG:22Z | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.60 | 1.36% | 119.50 | 119.00 | 120.00 | 121.00 | 117.30 | 117.50 | 691 | 22:50:06 |
From Aug 2023 to Aug 2024
Company announcement – No. 7 / 2024
Total number of shares and voting rights in Zealand Pharma at January 31, 2024
Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 3/2024 from January 12, 2024, Zealand announced an increase in share capital relating to private placement. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including January 31, 2024.
| Date | Number of shares(nominal value of DKK 1 each) | Share capital(nominal value in DKK) | Number of voting rights |
| January 31, 2024 | 62,512,622 | 62,512,622 | 62,512,622 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contact:
| Adam Lange Investor Relations Officer Zealand Pharma Email: akl@zealandpharma.com |
| Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com |
1 Year Zealand Pharma AS Chart |
1 Month Zealand Pharma AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
